دواعي استعمال تروسوبت نقط للعين 5 مل

Dorzolamide + timolol ophthalmic eye drops, 5 ml bottle (Kahira Pharmaceuticals, Egypt); antiglaucoma combination.

• Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension in patients insufficiently responsive to beta-blockers.DailyMed (U.S. National Library of Medicine)

• Bronchial asthma or history of asthma, or severe chronic obstructive pulmonary disease.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
• Sinus bradycardia, second- or third-degree AV block, overt cardiac failure, cardiogenic shock.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to any component of the product.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)

• Timolol is absorbed systemically: beta-blocker respiratory and cardiac reactions (including severe bronchospasm and cardiac failure) may occur.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
• Dorzolamide is a sulfonamide; rare fatal sulfonamide reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) can occur; discontinue at first sign of hypersensitivity.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
• May mask signs of hypoglycaemia and of thyrotoxicosis; may potentiate muscle weakness in myasthenia gravis.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)

• Oral carbonic anhydrase inhibitorsAdditive systemic effects; concomitant use not recommended.DailyMed (U.S. National Library of Medicine)
• Oral beta-blockers; calcium antagonists; digitalis; CYP2D6 inhibitors (e.g., quinidine, SSRIs)Possible additive beta-blockade, AV conduction disturbances, hypotension or bradycardia.DailyMed (U.S. National Library of Medicine)

• Timolol is detected in human milk; decide whether to discontinue nursing or the drug.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)

• دورزولاميد: Inhibits carbonic anhydrase II in the ciliary processes, decreasing aqueous humour secretion (directory pharmacology note).